Background: Diabetes is a noncommunicable disease caused by high levels of blood glucose, and it is currently one of the most important public health problems in the world. It is important to know the prevalence of diabetes, the factors affecting blood glucose levels, and the percentage of people with diabetes taking medications. Data and Methods Data and Methods: We analyzed the distribution of blood glucose levels and prevalence of diabetes using 10,917,173 observations obtained from the JMDC Claims Database in Japan. The factors that may affect blood glucose levels were analyzed by a regression model using 5,472,205 observations. Treatment with diabetes medications was analyzed with 9,932,854 and 5,466,361 observations using a method to approximate the inverse of probability by a continuous piecewise linear function. Results: The prevalence of diabetes in 2019 was estimated to be 9.63% in males and 5.33% in females ages 20 - 79; 10.78% and 7.04% for ages 20 - 89; and 10.93% and 7.65% for ages 20 - 99, respectively. In addition to age and gender, the important variables affecting blood glucose levels were BMI, SBP, Triglyceride, ALT, AST and GGP. The percentage taking medications increased up to a blood glucose level of around 175 mg/dL, but declined over that. Conclusion: The prevalence of diabetes in Japan was estimated using a very large dataset, and considering age, gender, and time trends. Some variables may be effective for controlling blood glucose levels. Nearly half of those at a serious stage of diabetes took no medications. Proper medical care for these individuals is necessary to prevent worsening diabetes and serious complications. Limitations: The dataset was observatory, and did not include those age 80 or over. Revising medical care systems to include those outside of hospitals is necessary; however, practical approaches have not yet been developed.
References
[1]
World Health Organization (2021) Diabetes.
https://www.who.int/health-topics/diabetes#tab=tab_1
[2]
World Health Organization (2021) Diabetes.
https://www.who.int/news-room/fact-sheets/detail/diabetes
[3]
International Diabetes Federation (2019) IDF Diabetes Atlas, Ninth Edition.
https://diabetesatlas.org/en
[4]
Gregg, E., Buckley, J., Ali, M., et al. (2021) Improving Health Outcomes of People with Diabetes Mellitus: Target Setting to Reduce the Global Burden of Diabetes Mellitus by 2030. WHO, Geneva.
https://www.who.int/publications/m/item/improving-health-outcomes-of-people-with-diabetes-mellitus
[5]
Center for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services (2020) National Diabetes Statistics Report 2020.
https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
[6]
American Diabetes Association ADA (2018) Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care, 41, 917-928. https://doi.org/10.2337/dci18-0007
[7]
ADA (2021) Diagnosis. https://www.diabetes.org/a1c/diagnosis
[8]
ADA (2021) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44, S15-S33. https://doi.org/10.2337/dc21-S002
International Diabetes Foundation IDF (2021) About Diabetes.
https://www.idf.org/aboutdiabetes/complications.html
[11]
Mauricio, D., Alonso, N. and Gratacòs, M. (2020) Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. Trends in Endocrinology & Metabolism, 31, 287-295. https://doi.org/10.1016/j.tem.2020.01.007
[12]
Ndjaboue, R., Farhat, I., Ferlatte, C.A., et al. (2020) Predictive Models of Diabetes Complications: Protocol for a Scoping Review. Systematic Reviews, 9, 137.
https://doi.org/10.1186/s13643-020-01391-w
[13]
Birkeland, K.I., Bodegard, J., Eriksson, J.W., et al. (2020) Heart Failure and Chronic Kidney Disease Manifestation and Mortality Risk Associations in Type 2 Diabetes: A Large Multinational Cohort Study. Diabetes, Obesity and Metabolism, 22, 1607-1618. https://doi.org/10.1111/dom.14074
[14]
Kraker, K., Herse, F., Golic, M., et al. (2020) Effects of Empagliflozin and Target Organ Damage in a Novel Rodent Model of Heart Failure Induced by Combined Hypertension and Diabetes. Scientific Reports, 10, Article No. 14061.
https://doi.org/10.1038/s41598-020-70708-5
[15]
Zareini, B., Blanche, P. and D’Souza, M. (2020) Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study. Circulation: Cardiovascular Quality and Outcomes, 13, e006260.
https://doi.org/10.1161/CIRCOUTCOMES.119.006260
[16]
Al-Brakati A., Albarakati, A.J.A., Daabo, H.M.A., et al. (2020) Neuromodulatory Effects of Green Coffee Bean Extract against Brain Damage in Male Albino Rats with Experimentally Induced Diabetes. Metabolic Brain Disease, 35, 1175-1187.
https://doi.org/10.1007/s11011-020-00583-6
[17]
McCrimmon, R.J. (2021) Consequences of Recurrent Hypoglycaemia on Brain Function in Diabetes. Diabetologia, 64, 971-977.
https://doi.org/10.1007/s00125-020-05369-0
[18]
Wicha, P., Das, S. and Mahakkanukrauh, P. (2021) Blood-Brain Barrier Dysfunction in Ischemic Stroke and Diabetes: The Underlying Link, Mechanisms and Future Possible Therapeutic Targets. Anatomy & Cell Biology, 54, 165-177.
https://doi.org/10.5115/acb.20.290
[19]
Yang, Y., Xiang, P., Chen, Q., et al. (2021) The Imbalance of PGD2-DPs Pathway Is Involved in the Type 2 Diabetes Brain Injury by Regulating Autophagy. International Journal of Biological Sciences, 17, 3993-4004.
https://doi.org/10.7150/ijbs.60149
[20]
Konstantinidis, L., Carron, T., de Ancos, E., et al. (2017) Awareness and Practices Regarding Eye Diseases among Patients with Diabetes: A Cross Sectional Analysis of the CoDiab-VD Cohort. BMC Endocrine Disorders, 17, 56.
https://doi.org/10.1186/s12902-017-0206-2
[21]
Bakris, L., Agarwal, R., Anker, S.D., et al. (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine, 383, 2219-2229. https://doi.org/10.1056/NEJMoa2025845
[22]
Rangaswami, J., Bhalla, V., de Boer, I.H., et al. (2020) Cardiorenal Protection with the Newer Antidiabetic Agents in Patients with Diabetes and Chronic Kidney Disease: A Scientific Statement from the American Heart Association. Circulation, 142, e265-e286. https://doi.org/10.1161/CIR.0000000000000935
[23]
Bhatt, D.L., Szarek, M., Pitt, B. et al. (2021) Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 384, 129-139.
https://doi.org/10.1056/NEJMoa2030186
[24]
Li, H., Lu, W., Wang, A. et al. (2021) Changing Epidemiology of Chronic Kidney Disease as a Result of Type 2 Diabetes Mellitusfrom 1990 to 2017: Estimates from Global Burden of Disease 2017. Journal of Diabetes Investigation, 12, 346-356.
https://doi.org/10.1111/jdi.13355
[25]
Stempniewicz, N., Vassalotti, J.A., Cuddeback, J.K. et al. (2021) Chronic Kidney Disease Testing among Primary Care Patients with Type 2 Diabetes across 24 U.S. Health Care Organizations. Diabetes Care, 44, 2000-2009.
https://doi.org/10.2337/dc20-2715
[26]
Fogagnolo, P., Melardi, E., Tranchina, L., et al. (2020) Topical Citicoline and Vitamin B12 versus Placebo in the Treatment of Diabetes Related Corneal Nerve Damage: A Randomized Double-Blind Controlled Trial. BMC Ophthalmology, 20, 315.
https://doi.org/10.1186/s12886-020-01584-w
[27]
Jende, J.M.E., Groener, J.B., Kender, Z. et al. (2020) Troponin T Parallels Structural Nerve Damage in Type 2 Diabetes: A Crosssectional Study Using Magnetic Resonance Neurography. Diabetes, 69, 713-723. https://doi.org/10.2337/db19-1094
[28]
Kim, S.H., Park, T.S. and Jin, H.Y. (2020) Metformin Preserves Peripheral Nerve Damage with Comparable Effects to Alpha Lipoic Acid in Streptozotocin/High-Fat Diet Induced Diabetic Rats. Diabetes & Metabolism Journal, 44, 842-853.
https://doi.org/10.4093/dmj.2019.0190
[29]
Ferdousi, M., Kalteniece, A., Azmi, S., et al. (2021) Diagnosis of Neuropathy and Risk Factors for Corneal Nerve Loss in Type 1 and Type 2 Diabetes: A Corneal Confocal Microscopy Study. Diabetes Care, 44, 150-156.
https://doi.org/10.2337/dc20-1482
[30]
Gentile S., Guarino, G.. Corte, T.D., et al. (2020) Insulin-Induced Skin Lipohypertrophy in Type 2 Diabetes: A Multicenter Regional Survey in Southern Italy. Diabetes Therapy, 11, 2001-2017. https://doi.org/10.1007/s13300-020-00876-0
[31]
Contardi, M., Lenzuni, M., Fiorentini, F., et al. (2021) Hydroxycinnamic Acids and Derivatives Formulations for Skin Damages and Disorders: A Review. Pharmaceutics, 13, 999. https://doi.org/10.3390/pharmaceutics13070999
[32]
Wen, Q. and Chen, Q. (2020) An Overview of Ozone Therapy for Treating Foot Ulcers in Patients with Diabetes. American Journal of the Medical Sciences, 360, 112-119. https://doi.org/10.1016/j.amjms.2020.05.012
[33]
Yesurathinam, H.J. and Jebakumar, A.Z. (2021) An Experimental Study to Assess the Knowledge about Foot Care before and after Education among Type 2 Diabetic Adult in the Eastern Province Region of Kingdom of Saudi Arabia. Annals of the Romanian Society for Cell Biology, 25, 4306-4313.
[34]
Gu, S., Wang, X., Shi, L., et al. (2020) Health-Related Quality of Life of Type 2 Diabetes Patients Hospitalized for a Diabetes-Related Complication. Quality of Life Research, 29, 2695-2704. https://doi.org/10.1007/s11136-020-02524-3
[35]
Kurkela, O., Forma, L., Ilianne-Parikka, P., et al. (2021) Association of Diabetes Type and Chronic Diabetes Complications with Early Exit from the Labour Force: Register-Based Study of People with Diabetes in Finland. Diabetologia, 64, 795-804.
https://doi.org/10.1007/s00125-020-05363-6
[36]
Wang, M., Yang, Y. and Liao, Z. (2020) Diabetes and Cancer: Epidemiological and Biological Links. World Journal of Diabetes, 11, 227-238.
https://doi.org/10.4239/wjd.v11.i6.227
[37]
Yuan, S., Kar, S., Carter, P. et al. (2020) Is Type 2 Diabetes Causally Associated with Cancer Risk? Evidence from a Two-Sample Mendelian Randomization Study. Diabetes, 69, 1588-1596. https://doi.org/10.2337/db20-0084
[38]
Ling, S., Brown, K., Miksza, J.K. et al. (2021) Risk of Cancer Incidence and Mortality Associated with Diabetes: A systematic Review with Trend Analysis of 203 Cohorts. Nutrition, Metabolism & Cardiovascular Diseases, 31, 14-22.
https://doi.org/10.1016/j.numecd.2020.09.023
[39]
WHO (2020) World Health Statistics 2020: Monitoring Health for the SDGs, Sustainable Development Goals. https://apps.who.int/iris/handle/10665/332070
[40]
WHO (2021) COVID-19 Significantly Impacts Health Services for Noncommunicable Diseases.
https://www.who.int/news/item/01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-diseases
[41]
Kumar, A., Arora, A., Sharma, P., et al. (2020) Is Diabetes Mellitus Associated with Mortality and Severity of COVID-19? A Meta-Analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14, 535-545.
https://doi.org/10.1016/j.dsx.2020.04.044
[42]
Morieri, M.L., Longato, E. and Avogaro, A. (2020) Prevalence and Impact of Diabetes among People Infected with SARS-CoV-2. Journal of Endocrinological Investigation, 43, 867-869. https://doi.org/10.1007/s40618-020-01236-2
[43]
Rubino, F., Amiel, S.A., Zimmet, P., et al. (2020) New-Onset Diabetes in Covid-19. New England Journal of Medicine, 383, 789-790.
https://doi.org/10.1056/NEJMc2018688
[44]
Seiglie, J., Platt, J., Cromer, S.J., et al. (2020) Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized with COVID-19. Diabetes Care, 43, 2938-2944.
https://doi.org/10.2337/dc20-1506
[45]
Scheen, A.J. (2021) Statins and Clinical Outcomes with COVID-19: Meta-Analyses of Observational Studies. Diabetes & Metabolism, 47, Article ID: 101220.
https://doi.org/10.1016/j.diabet.2020.101220
[46]
Selvin, E. and Juraschek, S.P. (2020) Diabetes Epidemiology in the COVID-19 Pandemic. Diabetes Care, 43, 1690-1694. https://doi.org/10.2337/dc20-1295
[47]
Singh, A.K. and Singh, R. (2020) Hyperglycemia without Diabetes and New-Onset Diabetes Are Both Associated with Poorer Outcomes in COVID-19. Diabetes Research and Clinical Practice, 167, Article ID: 108382.
https://doi.org/10.1016/j.diabres.2020.108382
[48]
Singh, A.K., Gupta, R., Ghosh, A., et al. (2020) Diabetes in COVID-19: Prevalence, Pathophysiology, Prognosis and Practical Considerations. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14, 303-310.
https://doi.org/10.1016/j.dsx.2020.04.004
[49]
Domenico Accili (2021) Can COVID-19 Cause Diabetes?. Nature Metabolism, 3, 123-125. https://doi.org/10.1038/s42255-020-00339-7
[50]
Gregory, J.M., Slaughter, J.C., Duffus, S.H. et al. (2021) COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Impact in Type 1 and Type 2 Diabetes. Diabetes, 44, 526-532.
https://doi.org/10.2337/dc20-2260
[51]
Lim, S., Bae, J.H., Kwon, H. et al. (2021) COVID-19 and Diabetes Mellitus: From Pathophysiology to Clinical Management. Nature Reviews Endocrinology, 17, 11-30.
https://doi.org/10.1038/s41574-020-00435-4
[52]
McGurnaghan, S.J., Weir, A., Bishop, J., et al. (2021) Risks of and Risk Factors for COVID-19 Disease in People with Diabetes: A Cohort Study of the Total Population of Scotland. The Lancet Diabetes & Endocrinology, 9, 82-93.
https://doi.org/10.1016/S2213-8587(20)30405-8
[53]
Wu, Z.., Tang, Y. and Cheng, Q. (2021) Diabetes Increases the Mortality of Patients with COVID-19: A Meta-Analysis. Acta Diabetologica, 58, 139-144.
https://doi.org/10.1007/s00592-020-01546-0
[54]
Ministry of Health, Labour and Welfare (2020) Heisei 30 Nendo Kokumun Iryouhi no Gaikyou (Summary of the National Medical Expenditures, Fiscal Year 2018). Tokyo. (In Japanese)
[55]
Ministry of Health, Labour and Welfare (2020) Heisei 29 Nen Kanja Chousa No Gaikyo (Summary of the Patient Survey, 2017). Tokyo. (In Japanese)
[56]
Ministry of Health, Labour and Welfare (2020) The National Health and Nutrition Survey in Japan, 2019. Tokyo. (In Japanese)
[57]
Nawata, K. and Kimura, M. (2017) An Analysis of the Medical Costs of and Factors Affecting Diabetes Using the Medical Checkup and Payment Dataset in Japan: Can We Reduce the Prevalence of Diabetes? Health, 9, 1113-1127.
https://doi.org/10.4236/health.2017.98081
[58]
Araki E., Goto, A., Kondo, T., et al. (2020) Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 11, 165-223.
https://doi.org/10.1007/s13340-020-00439-5
[59]
WHO (2017) WHO Model List of Essential Medicines.
http://www.who.int/medicines/publications/essentialmedicines/en
[60]
WHO (2018) Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Non-Pregnant Adults with Diabetes Mellitus. https://apps.who.int/iris/handle/10665/272433
[61]
Chung, W.K., Erion, K., Florez, J.C., et al. (2020) Precision Medicine in Diabetes: A Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 63, 1671-1693.
https://doi.org/10.1007/s00125-020-05181-w
ADA (2021) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44, S111-S124.
https://doi.org/10.2337/dc21-S009
[64]
Carter, A. and Cherney, K. (2021) A Complete List of Diabetes Medications. Heathline. https://www.healthline.com/health/diabetes/medications-list#type-2-diabetes
[65]
Cunha, J.P. (2021) New Diabetes Medications List. RxList.
https://www.rxlist.com/new_diabetes_medications_list/drugs-condition.htm
[66]
Diabetes Teaching Center at the University of California, San Francisco (2021) Table of Medications: Diabetes Education Online.
https://dtc.ucsf.edu/types-of-diabetes/type2/treatment-of-type-2-diabetes/medications-and-therapies/type-2-non-insulin-therapies/table-of-medications
[67]
Drugs.com (2021) Medications for Diabetes, Type 2.
https://www.drugs.com/condition/diabetes-mellitus-type-ii.html
[68]
National Institute of Diabetes and Digestive and Kidney Diseases (2021) Insulin, Medicines, & Other Diabetes Treatments.
https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments
[69]
Statistic Bureau of Japan, Ministry of Internal Affairs and Communications (2020) Population by Age (Single Years), Sex and Sex Ratio. Tokyo.
[70]
Nawata, K. and Kawabuchi, K. (2015) Financial Sustainability of the Japanese Medical Payment System: Analysis of the Japanese Medical Expenditure for Educational Hospitalization of Patients with Type 2 Diabetes. Health, 7, 1007-1021.
https://doi.org/10.4236/health.2015.78118
[71]
Nawata, K. and Kawabuchi, K. (2016) Comparison of the Length of Stay and Medical Expenditures among Japanese Hospitals for Type 2 Diabetes Treatments: The Box-Cox Transformation Model under Heteroscedasticity. Health, 8, 49-63.
https://doi.org/10.4236/health.2016.81007
